World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
44259
World Ranking
8810
National Ranking
4539

Andrew Siderowf publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrew Siderowf sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 310 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrew Siderowf D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew Siderowf sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrew Siderowf is affiliated with the University of Pennsylvania in the United States. Their research focuses primarily on the field of medicine, with a specialization in neurology, physiology, psychiatry and mental health, cognitive neuroscience, and sensory systems. Their work addresses various neurological disorders with a strong emphasis on Parkinson's disease mechanisms and treatments. Other prominent topics in their research include Alzheimer's disease research and treatments, dementia and cognitive impairment research, botulinum toxin and related neurological disorders, autism spectrum disorder research, and olfactory and sensory function studies.

They have contributed to multiple research papers, including:

  • Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study (2023, The Lancet Neurology)
  • A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research (2024, The Lancet Neurology)
  • Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020, JAMA Neurology)
  • Trial of Cinpanemab in Early Parkinson's Disease (2022, New England Journal of Medicine)
  • Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease (2022, Science Translational Medicine)

Andrew Siderowf frequently collaborates with several researchers, including:

  • Kenneth Marek
  • Daniel Weintraub
  • Lana M. Chahine
  • Michael C. Brumm
  • Tanya Simuni

The scientist publishes often in these venues:

  • Neurology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Movement Disorders
  • Journal of Parkinson s Disease
  • npj Parkinson s Disease

Best Publications

  • Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

    Christopher G. Goetz;Barbara C. Tilley;Stephanie R. Shaftman;Glenn T. Stebbins

  • Projected number of people with parkinson disease in the most populous nations, 2005 through 2030

    E. R. Dorsey;R. Constantinescu;R. Constantinescu;J. P. Thompson;K. M. Biglan

  • The Parkinson Progression Marker Initiative (PPMI)

    Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  • Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients

    Daniel Weintraub;Juergen Koester;Marc N. Potenza;Andrew D. Siderowf

  • Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease

    S. Hoops;S. Nazem;A. D. Siderowf;J. E. Duda

  • Association of dopamine agonist use with impulse control disorders in Parkinson disease.

    Daniel Weintraub;Andrew D. Siderowf;Marc N. Potenza;Joseph Goveas

  • Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology

    D. Cella;J. S. Lai;C. J. Nowinski;D. Victorson

  • Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

    John L Robinson;Edward B Lee;Sharon X Xie;Lior Rennert

  • A controlled trial of rasagiline in early Parkinson disease: The tempo study

    Andrew Siderowf;Matthew Stern;Ira Shoulson;Karl Kieburtz

  • The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort

    Kenneth Marek;Sohini Chowdhury;Andrew Siderowf;Shirley Lasch

  • Validation of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease

    Daniel Weintraub;Staci Hoops;Judy A. Shea;Judy A. Shea;Kelly E. Lyons

  • Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.

    Hanae Nakashima-Yasuda;Kunihiro Uryu;John Robinson;Sharon X. Xie

  • Impulse control disorders in parkinson disease: A multicenter case–control study

    Valerie Voon;Mandy Sohr;Anthony E. Lang;Marc N. Potenza

  • Montreal Cognitive Assessment Performance in Patients with Parkinson’s Disease with “Normal” Global Cognition According to Mini-Mental State Examination Score

    Sarra Nazem;Andrew D. Siderowf;John E. Duda;Tom Ten Have

  • Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease

    Ju-Hee Kang;Ju-Hee Kang;David J. Irwin;Alice S. Chen-Plotkin;Andrew Siderowf

  • CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

    A. Siderowf;S.X. Xie;H. Hurtig;D. Weintraub

  • A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

    M Flint Beal;David Oakes;Ira Shoulson

  • Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients

    Atsushi Umemura;Jurg L. Jaggi;Howard I. Hurtig;Andrew D. Siderowf

  • Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale

    Daniel Weintraub;Eugenia Mamikonyan;Kimberly Papay;Judith A. Shea;Judith A. Shea

  • Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study

    B Ravina;M Putt;A Siderowf;J T Farrar

Frequent Co-Authors

Daniel Weintraub
Daniel Weintraub University of Pennsylvania
Matthew B. Stern
Matthew B. Stern University of Pennsylvania
John E. Duda
John E. Duda University of Pennsylvania
John Q. Trojanowski
John Q. Trojanowski University of Pennsylvania
Howard I. Hurtig
Howard I. Hurtig University of Pennsylvania
Sharon X. Xie
Sharon X. Xie University of Pennsylvania
Caroline M. Tanner
Caroline M. Tanner University of California, San Francisco
Danna Jennings
Danna Jennings Denali Therapeutics (United States)
Murray Grossman
Murray Grossman University of Pennsylvania
Mark A. Mintun
Mark A. Mintun University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean becoming a doctor. There are many alternative and in-demand healthcare roles that offer flexibility, strong job outlook, and rewarding career advancement possibilities. For example, those interested in administrative work may consider taking medical coding and billing classes online with financial aid, which can lead to vital roles in healthcare documentation and support.

Nursing remains one of the most popular and accessible entry points to healthcare. You may wonder, do all nursing schools require the teas? The answer is no—some programs do not require the TEAS or HESI exams, making the admissions process less daunting for prospective students.

For individuals seeking leadership roles, pursuing an accelerated healthcare administration degree online can help open doors to management and executive positions in hospitals, clinics, and other medical organizations.

Nurses aiming to advance their practice may also look into asn to nurse practitioner programs, which allow registered nurses to bridge their credentials and qualify for higher-responsibility roles in clinical care.

Best Scientists Citing Andrew Siderowf

Trending Scientists

Recently Published Articles